Last reviewed · How we verify

Dexmedetomidine for sedation

Southeast University, China · FDA-approved active Small molecule

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation and analgesia by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation and analgesia by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation in intensive care unit (ICU) patients, Procedural sedation, Perioperative sedation and analgesia.

At a glance

Generic nameDexmedetomidine for sedation
Also known asControl drug for sedation
SponsorSoutheast University, China
Drug classAlpha-2 adrenergic receptor agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaAnesthesia and Sedation
PhaseFDA-approved

Mechanism of action

By binding to alpha-2 adrenergic receptors, dexmedetomidine reduces norepinephrine release and enhances inhibitory neurotransmission, resulting in sedation, anxiolysis, and analgesia without respiratory depression. This mechanism allows patients to remain arousable and responsive to stimuli while sedated, making it suitable for procedural and ICU sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: